The Brain & Performance Centre Raises Autism Awareness with Everest Base Camp Trek Initiative
In honour of Autism Awareness Month, Dubai-based Brain & Performance Centre — a DP World company — is embarking on an extraordinary mission to shine a spotlight on Autism Spectrum Disorder (ASD). Backed by a powerful message of resilience and inclusion, the centre is supporting a high-profile Everest Base Camp trek led by famed British adventurer and former UK Special Forces operator, Ant Middleton.
The awareness initiative, launched this April, unites local and global organisations to promote evidence-based, multidisciplinary support for children facing cognitive and physical developmental challenges in the UAE. A team from The Brain & Performance Centre will participate in the expedition, with the experience being documented and shared across media platforms to extend the reach of the campaign.
'Every child deserves the opportunity to reach their full potential,' said Dr. Craig Cook, CEO of The Brain & Performance Centre. 'Through this campaign, we're raising awareness and mobilising support for children with autism and their families.'
Ant Middleton, who is leading the trek, described the mission as a symbol of the strength shown by children and families affected by ASD:
'Trekking to Everest Base Camp is a powerful metaphor for their daily battles and triumphs. It's an honour to support such an important cause.'
💡 Advancing Autism Care in the UAE
At the heart of the initiative is The Brain & Performance Centre's pioneering youth treatment programme, designed using internationally recognised medical research. The programme, exclusive to Dubai, supports children with autism, cerebral palsy, traumatic brain injuries, and other developmental challenges.
The treatment model incorporates hyperbaric oxygen therapy (HBOT), tailored cognitive and physical training, and nutritional planning — offering children improved mobility, cognitive function, and quality of life.
Before enrolment, every child undergoes a comprehensive medical assessment, and only those deemed likely to benefit are admitted. This ensures each child receives the best possible chance at progress, while maintaining the highest standards of ethics, privacy, and regulatory compliance.
🎗️ How You Can Support
A dedicated fundraising campaign is currently underway to assist families in accessing treatment. Contributions can directly support the care of children with ASD in the UAE.
Interested donors and supporters can contact: Dr. Craig Cook
CEO, The Brain & Performance Centre
📧 craig@braindubai.ae
As the team treks to Everest Base Camp, the mission is clear: to raise voices, inspire change, and help children with autism thrive. Through determination, innovation, and community support, The Brain & Performance Centre is scaling new heights — both literally and figuratively — in the pursuit of inclusive healthcare.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Trade Arabia
5 days ago
- Trade Arabia
M42, partners launch liquid biopsy testing in UAE
M42, a global health leader powered by technology, continues to pioneer artificial intelligence (AI) and medical and clinical solutions as part of its mission to revolutionise health in the UAE and globally. In a major advancement for precision oncology, M42 announced a strategic collaboration with AstraZeneca and SOPHiA Genetics to bring cutting-edge liquid biopsy testing to the UAE, aimed at advancing cancer diagnosis, informing treatment decisions, and enabling faster, accurate biomarker testing across a broad range of cancers. As part of the collaboration, M42 will integrate SOPHiA GENETICS' MSK-ACCESS, powered with SOPHiA DDM technology, into its testing infrastructure, enabling non-invasive genomic profiling of cancers through a simple blood draw. This approach does not replace but rather complements routine cancer screenings and is designed for patients who are unable to undergo a solid tumor biopsy, enabling them to be matched with a precision therapy tailored to their specific cancer profile. Over the next 12 months, the partnership will enable liquid biopsy testing access across select leading hospitals across the UAE, providing patients with faster, less invasive biomarker insights compared to traditional tissue biopsies, while also strengthening testing infrastructure and capabilities for a wide range of cancers in the UAE. The new testing programme will initially target lung, ovarian, breast, colorectal, and pancreatic cancers, among others, addressing some of the most critical cancer burdens in the region. Validation studies are set to commence shortly at Cleveland Clinic Abu Dhabi, marking a key milestone toward the full clinical launch planned for the latter part of Q2 2025. Over time, the collaboration will serve as a foundation for broader expansion across the Middle East, excluding Saudi Arabia, delivering world-class precision oncology solutions to a wider population. Albarah El-khani, Senior Vice President, Operations, Integrated Health Solutions at M42, said: "At M42, we are committed to transforming care through innovation and collaboration. By partnering with AstraZeneca and SOPHiA GENETICS, we are bringing world-class liquid biopsy technologies to the UAE, empowering clinicians to deliver more precise and less invasive cancer care. This collaboration reflects our vision of democratizing health by making advanced diagnostics accessible to more patients, supporting not just early diagnosis but also real-time treatment monitoring and cost-effective, precise, predictive, and personalized care." Sameh El Fangary, Cluster President GCC, AstraZeneca, shared:"At AstraZeneca, we are leading the way in the application of precision medicine. Our work, and our collaborations with partners across industry, are driving towards better treatments for patients as well as a more sustainable future for healthcare systems. Through our latest partnerships, we are committed to transforming cancer care for millions in the region by advancing early diagnosis and optimizing patient pathways from detection to therapy.'
Trade Arabia
5 days ago
- Trade Arabia
Dubai hospitals to use geko device for patients
Dubai-based Genesis Healthcare, Dubai London Hospital and Mediclinic Parkview Hospital have adopted Sky Medical's innovative geko device to accelerate chronic wound healing (leg ulcers), prevent and treat lower limb oedema (swelling) and to prevent venous thromboembolism (VTE - blood clots) in medically ill and immobile patients. The size of a small wrist-watch, the geko device is a wearable neuromuscular electrostimulator that is applied to the surface of the skin just below the knee. It delivers a gentle electrical pulse, once per second, to the common peroneal nerve, activating the calf and foot muscle pumps, increasing venous, arterial, and microcirculatory blood flow at a rate equal to 60% of walking, replicating the effects of exercise without a patient having to move, said global medical device manufacturer Sky Medical Technology. Dr Ibrahim Riza, Consultant Vascular and Endovascular Surgeon, said: 'The geko device has been a game-changer in my practice. External compression, multi-layer bandaging, and drugs are the current standard of care for increasing blood circulation, but they do not work for all conditions. External compression and bandaging therapies can be complex to apply and uncomfortable to wear, leading to poor patient compliance, and drugs can carry an unpredictable bleed risk. The geko device overcomes these challenges and is uniquely positioned to address significant unmet needs when drug and current compression devices are impractical or contraindicated. As well as chronic wound healing and post-stroke VTE prevention, the geko device is highly effective in addressing lymphedema and maternity and travel-related oedema. 'One of its biggest advantages is ease of use. The geko device is lightweight, silent, and completely non-invasive. Patients can wear it while sitting, lying down, and moving around, making it ideal for immobile patients and for those who are active in managing their recovery following surgery. By offering my patients the geko device, I provide them with a safe, comfortable, and effective way to support their vascular health, without the need for drugs or bulky equipment.' Sky Medical Technology CEO and Founder Bernard Ross: 'I am delighted that Dr Ibrahim Riza and his clinical team are benefiting from the geko device, which provides an effective and non-invasive way to manage vascular health and enhance recovery. We are proud to be partnered with hospitals and clinicians in Dubai who share our vision for advanced therapies that can deliver better patient outcomes and healthcare system savings.'
Trade Arabia
6 days ago
- Trade Arabia
Delta Coatings completes roof insulation work at Rashid Centre
Delta Coatings International, a global leader in polyurea protective coatings and sustainable infrastructure solutions, said it has successfully completed a charitable project delivering new roof insulation and waterproofing at the Rashid Centre for People of Determination in Dubai. In this latest charitable initiative, Delta Coatings had supplied and applied a full roof insulation and waterproofing system. The solution combined high-performance polyurethane (PU) foam insulation with Delta's cutting-edge DeltaShield TC 100 polyurea coating, delivering long-term protection against heat and moisture, crucial in the UAE's demanding climate, said the company in a statement. Established in 1994, the Rashid Centre has long been a beacon of hope and opportunity for people of determination from as young as four years old, providing a therapeutic, educational and vocational training environment for students with a variety of physical, sensory and learning disabilities. The centre has continually evolved to align with the UAE's inclusive vision, offering a curriculum empowering students to achieve independence and gainful employment. On the key initiative, Sales Director Paul Symons said: "This is about giving back to a country that has provided us with endless opportunities. Our gratitude goes out to the Rashid Centre for People of Determination for allowing us to contribute and for giving us an opportunity to see the remarkable environment they've cultivated." "It's partnerships like these that reinforce the power of collaboration and compassion. Supporting this fantastic institution aligns perfectly with our core values and CSR objectives of empowering communities and enhancing lives through meaningful, impact-driven initiatives," he added. General Manager Belvin Marx, who led the technical execution of the project, said: "We take immense pride in supporting institutions like the Rashid Centre. The waterproofing and insulation solution not only improves building performance but also contributes to a safer, more comfortable learning environment for students of determination." This initiative is one of several ways Delta is integrating environmental, social and governance (ESG) principles into its operations. The company's new headquarters and manufacturing facility in Dubai Industrial City, which is currently under development, will feature rooftop solar energy systems and sustainably sourced building materials to lower overall emissions and energy use.
